Drug development
Colin Kerr
Published: Monday, July 3, 2017
Novaliq GmbH has announced the successful application of a first-in-class ocular neuropathic pain and anti-inflammatory cannabinoid-based dry eye disease (DED) treatment approach, in collaboration with the University of Cologne, Germany.
“Based on solid results of our ongoing test series, we expect a significant impact of Novaliq’s first-in class Nov-07 programme, in comparison with existing DED drugs on an established DED mouse model,” said Philipp Steven MD, Principle Investigator, Ocular Surface Group at the Department of Ophthalmology, University of Cologne, Germany.
www.novaliq.com
Tags: industry
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.